SCHEMBL1864822

SCHEMBL1864822

O=C(O)CNc1c2ccccc2nc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 10/20 0.61
KDM4E B2RXH2 7/20 0.61
GAA P10253 7/20 0.61
RAD52 P43351 5/20 0.61
GLA P06280 5/20 0.61
LMNA P02545 5/20 0.61
RAB9A P51151 4/20 0.61
ALDH1A1 P00352 3/20 0.61
MITF O75030 2/20 0.61
TTR P02766 1/20 0.61
KMT2A Q03164 7/20 0.58
TOP2A P11388 4/20 0.54
ATM Q13315 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
HPGD P15428 1/20 0.51
MAPT P10636 5/20 0.51
NPC1 O15118 3/20 0.51
MEN1 O00255 3/20 0.51
GFER P55789 2/20 0.51
NPSR1 Q6W5P4 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9295700 0.87 POLB (0.51) POLBKDM4EGAARAD52GLA
SCHEMBL14740610 0.85 POLB (0.61) POLBKDM4EGAARAD52GLA
SCHEMBL17423141 0.83 TOP2A (0.59) POLBKDM4EGAARAD52GLA
SCHEMBL15867121 0.82 POLB (0.63) POLBKDM4EGAARAD52GLA
SCHEMBL3360006 0.82 POLB (0.67) POLBKDM4EGAARAD52GLA
SCHEMBL4157722 0.79 TOP2A (0.75) POLBKDM4EGAARAD52GLA
SCHEMBL10135258 0.79 SIRT5 (0.51) POLBKDM4ERAD52LMNAALDH1A1
SCHEMBL15867118 0.78 POLB (0.67) POLBKDM4EGAARAD52GLA
SCHEMBL8269610 0.78 PDE10A (0.57) KDM4E
SCHEMBL7880366 0.78 POLB (0.78) POLBKDM4EGAARAD52GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108026018-B Diphenylacetylene compound 国立大学法人大阪大学 2021-01-15 CN disclosed
US-20180258141-A1 TOLAN COMPOUND OSAKA UNIVERSITY (JP) 2018-09-13 US disclosed
US-20160354533-A1 ADSORBING PATHOGEN-INACTIVATING COMPOUNDS WITH POROUS PARTICLES IMMOBILIZED IN A MATRIX CERUS CORPORATION (US) 2016-12-08 US disclosed
US-9259525-B2 Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix CERUS CORPORATION (US) 2016-02-16 US disclosed
EP-1508345-B1 System and method for the reduction of small organic compounds from blood products CERUS CORP (US) 2013-09-25 EP disclosed
EP-2493857-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES Ariel-University Research and Development Company Ltd. (IL) 2012-09-05 EP disclosed
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2012-08-30 US disclosed
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2012-08-30 US disclosed
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2012-08-30 US disclosed
WO-2011051950-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD (IL) 2011-05-05 WO disclosed
US-20010018179-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE CERUS CORPORATION 2001-08-30 US disclosed
US-20010009756-A1 FLOW DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS AND METHODS OF USE CERUS CORPORATION 2001-07-26 US disclosed
CN-1284896-A Flow device for the reduction of compounds from biological compositions and methods of use CERUS CORP (US) 2001-02-21 CN disclosed
CN-1284897-A Batch devices for reduction of compounds from biological compositions containing cells and methods of use CERUS CORP (US) 2001-02-21 CN disclosed
EP-1051249-A1 FLOW DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS AND METHODS OF USE Cerus Corporation (US) 2000-11-15 EP disclosed
EP-1044066-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE Cerus Corporation (US) 2000-10-18 EP disclosed
EP-0954374-A1 METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS Cerus Corporation (US) 1999-11-10 EP disclosed
WO-1999034914-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1999034915-A1 FLOW DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1998030327-A1 METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS CERUS CORPORATION (US) 1998-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220537-A1 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES MPG, PRMT9, AADAT POLB 842/4885KDM4E 502/4885GAA 2176/4885
US-20180258141-A1 TOLAN COMPOUND TAP1, GRN, TSG101 POLB 578/4885KDM4E 4844/4885GAA 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.